FR19C1014I1 - USE OF N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS - Google Patents

US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors CN101486682B (en) * 2002-03-13 2013-08-14 阵列生物制药公司 N3 alkylated benzimidazole derivatives as MEK inhibitors WO2004054515A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics US20060140872A1 (en) * 2003-02-26 2006-06-29 Kowa Co., Ltd. Novel signaling pathway for the production of inglammatory pain and neuropathy ES2331246T3 (en) * 2003-07-24 2009-12-28 Warner-Lambert Company Llc DERIVATIVES OF BENZAMIDAZOL AS INHIBITORS OF THE MEK. US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof BRPI0414581C1 (en) 2003-09-22 2021-05-25 Mei Pharma Inc compound, pharmaceutical composition comprising said compound and use of said compound US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof SI1682138T1 (en) * 2003-11-19 2011-04-29 Array Biopharma Inc Heterocyclic inhibitors of mek US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof RU2006121990A (en) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) ACT PROTEINKINASE INHIBITORS US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases PT1802579E (en) 2004-10-20 2014-02-17 Merck Serono Sa Derivatives of 3-arylaminopyridine DE602005016718D1 (en) * 2004-12-01 2009-10-29 Merck Serono Sa Coinsins Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRIDIN DERIVATIVE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors NZ587189A (en) 2005-05-18 2011-11-25 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof AU2006262259B2 (en) 2005-06-23 2013-03-14 Array Biopharma Inc. Process for preparing benzimidazole compounds WO2007002092A1 (en) * 2005-06-23 2007-01-04 Array Biopharma Inc. SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases CA3052368A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors US7968108B2 (en) * 2005-10-25 2011-06-28 Metbro Distributing L.P. Hydrogen cyanamide pesticide formulations US7572460B2 (en) * 2005-10-25 2009-08-11 Rodrigo Rodriguez-Kabana Hydrogen cyanamide pesticide formulations WO2007071951A1 (en) * 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer TWI405756B (en) * 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulphate CA2534243A1 (en) 2006-01-25 2007-07-25 Hydro Quebec Coated metal oxide particles with low dissolution rate, methods for their preparation and use in electrochemical systems GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors EP2012786B1 (en) * 2006-04-18 2010-10-06 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors JP5231411B2 (en) 2006-07-06 2013-07-10 アレイ バイオファーマ、インコーポレイテッド Dihydrothienopyrimidines as AKT protein kinase inhibitors DE602007011628D1 (en) 2006-07-06 2011-02-10 Array Biopharma Inc DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors KR101527232B1 (en) 2006-07-06 2015-06-09 어레이 바이오파마 인크. AKT cyclopenta [D] pyrimidine as a protein kinase inhibitor WO2008016123A1 (en) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR CN101583616B (en) * 2006-08-21 2012-05-30 健泰科生物技术公司 Aza-benzothiophenyl compounds and methods of use US20080085886A1 (en) * 2006-08-21 2008-04-10 Genentech, Inc. Aza-benzofuranyl compounds and methods of use AU2007286807B2 (en) * 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use ES2703723T3 (en) 2006-12-14 2019-03-12 Exelixis Inc Methods for using MEK inhibitors JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors CN101678001A (en) * 2007-04-13 2010-03-24 阿斯利康(瑞典)有限公司 Combination therapy comprising AZD2171 and AZD6244 or MEK-inhibitor II US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object US8258152B2 (en) 2007-06-12 2012-09-04 Genentech, Inc. N-substituted azaindoles and methods of use SI2173723T1 (en) * 2007-07-05 2011-12-30 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents EP2217234A2 (en) * 2007-10-15 2010-08-18 AstraZeneca AB Combinations of mek inhibitors with mtor inhibitors EP2227469B9 (en) 2007-11-12 2014-09-10 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors NZ586802A (en) 2007-12-19 2012-03-30 Genentech Inc Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases CN101903387B (en) 2007-12-19 2014-05-21 健泰科生物技术公司 8-anilin0imidaz0pyridines and application thereof as anti-cancer and/or anti-inflammatory agents BRPI0820696A2 (en) 2007-12-20 2019-09-24 Hoffmann La Roche substituted hydantoins as mek kinase inhibitors EP2220092B1 (en) 2007-12-21 2012-06-06 Genentech, Inc. Azaindolizines and methods of use BRPI0906798A2 (en) * 2008-01-09 2015-07-14 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors WO2009089453A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents JP5404622B2 (en) 2008-06-23 2014-02-05 パナソニック株式会社 Radio communication base station apparatus and reference signal allocation method AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors CA2727252A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use PE20110665A1 (en) 2008-08-04 2011-09-23 Merck Patent Gmbh COMPOUNDS DERIVED FROM N-CYCHHOHEXIL-3- (PHENYLAMINE) -ISONICOTINAMIDE AS MEK INHIBITORS CN101653607B (en) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides ES2399384T3 (en) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido substituted phenoxybenzamides US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Protein kinase inhibitors US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors MX2012015100A (en) 2010-06-25 2013-05-01 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors. US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity CA2812608C (en) 2010-10-06 2020-07-14 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor CA2822638C (en) 2010-12-22 2021-02-16 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs PT2655375E (en) 2010-12-23 2015-03-02 Sanofi Sa Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof BR112013025397A2 (en) 2011-04-01 2019-09-24 Deepak Sampath combination of a compound, compound of formula i or a pharmaceutically acceptable salt thereof, use, kit, product, method for treating a hyperproliferative disorder and method for treating an akt kinase-modulated disease or condition in a mammal CN104586861A (en) 2011-04-01 2015-05-06 基因泰克公司 Combinations of akt inhibitor compounds and abiraterone, and methods of use WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors EP2714037B1 (en) 2011-05-25 2016-07-13 Université Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors BR112014002353B1 (en) 2011-08-01 2022-09-27 Genentech, Inc USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion CN103764144B (en) * 2011-08-31 2016-07-20 诺华股份有限公司 PI3K inhibitor and the synergistic combination of mek inhibitor EP2750672A1 (en) * 2011-09-01 2014-07-09 Novartis AG Use of organic compound for the treatment of noonan syndrome EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors CN104011047A (en) 2011-10-14 2014-08-27 阵列生物制药公司 Polymorphic forms of selective HERB2 inhibitor ARRY-380 and pharmaceutical compositions containing them WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors EP2776025A1 (en) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors CA2856297C (en) 2011-11-23 2023-10-17 Medimmune, Llc Binding molecules specific for her3 and uses thereof WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists JP6158833B2 (en) 2012-01-09 2017-07-05 アローヘッド ファーマシューティカルズ インコーポレイテッド Organic composition for treating beta-catenin related diseases WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia CN103204822B (en) 2012-01-17 2014-12-03 上海科州药物研发有限公司 Benzoxazole compounds as protein kinase inhibitors, and preparation method and application thereof GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method AU2013235596B9 (en) 2012-03-20 2017-12-14 Amgen Inc. Combination therapy of a MEK inhibitor and IGF1R inhibitor CN104350415B (en) 2012-04-09 2018-01-16 思维奇材料公司 Transition material, and combinations thereof and manufacture method CN104508520B (en) 2012-05-29 2018-03-27 思维奇材料公司 Optical filter comprising variable transmittance layer EP2854779A1 (en) 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients AR091876A1 (en) * 2012-07-26 2015-03-04 Novartis Ag PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES WO2014027056A1 (en) 2012-08-17 2014-02-20 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib LT2903968T (en) 2012-10-02 2017-02-27 Gilead Sciences, Inc. Inhibitors of histone demethylases MX372708B (en) 2012-10-12 2020-05-29 Exelixis Inc Novel process for making compounds for use in the treatment of cancer JP6243918B2 (en) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド PKM2 modulators and methods for their use PT3702351T (en) 2012-10-19 2024-01-17 Array Biopharma Inc Formulation comprising a mek inhibitor US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction JP6437444B2 (en) * 2012-11-29 2018-12-12 ノバルティス アーゲー Pharmaceutical combination US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor JP2016508726A (en) 2013-02-22 2016-03-24 セルラー ダイナミクス インターナショナル， インコーポレイテッド Production of hepatocytes via forward programming with combined genetic and chemical manipulation WO2014133071A1 (en) 2013-02-27 2014-09-04 第一三共株式会社 Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway WO2014131777A1 (en) 2013-02-27 2014-09-04 Epitherapeutics Aps Inhibitors of histone demethylases KR102334260B1 (en) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 and alk2 inhibitors and methods for their use JP6449234B2 (en) 2013-03-21 2019-01-09 ノバルティス アーゲー Combination therapy AR097617A1 (en) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd ANTIBACTERIAL DERIVATIVES OF 2H-INDAZOL US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation ES2666130T3 (en) 2013-12-19 2018-05-03 Idorsia Pharmaceuticals Ltd Antibacterial derivatives of 1H-indazole and 1H-indole AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms CN104788365B (en) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 Pyrazinamide derivative, preparation method and application JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof AR099612A1 (en) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd ANTIBACTERIAL DERIVATIVES OF 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof EP3126345A1 (en) 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering JP2017515906A (en) 2014-05-16 2017-06-15 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Antibacterial quinazolone-4 (3H) -one derivative US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells RU2733735C2 (en) 2014-07-15 2020-10-06 Дженентек, Инк. Compositions for treating cancer using antagonists which bind to the pd-1 signaling pathway component and mek inhibitors US9802941B2 (en) 2014-08-27 2017-10-31 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT ES2952717T3 (en) 2014-10-14 2023-11-03 Novartis Ag Antibody molecules against PD-L1 and uses thereof US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies EA032416B1 (en) 2014-12-23 2019-05-31 Новартис Аг Triazolopyrimidine compounds and uses thereof JP6800859B2 (en) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド Methods and Compositions for Inducing Hematopoietic Cell Differentiation CN105566225A (en) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 Crystal forms of orally-taken mitogen-activated protein kinase inhibitor and preparation method of crystal forms JP2016155776A (en) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 Antitumor effect enhancer and antitumor agent BR112017018908A2 (en) 2015-03-10 2018-04-17 Aduro Biotech, Inc. compositions and methods for activating interferon gene stimulator-dependent signaling CA2976766A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors MA41866A (en) 2015-03-31 2018-02-06 Massachusetts Gen Hospital SELF-ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3 EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1 US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3 AR105646A1 (en) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd ANTIBACTERIAL AGENTS OF 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA SUBSTITUTED US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor AU2016314082B2 (en) 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof AR105889A1 (en) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd ANTIBACTERIAL COMPOUNDS 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA SUBSTITUTED KR102746585B1 (en) 2015-10-16 2024-12-24 페이트 세러퓨틱스, 인코포레이티드 A platform for inducing and maintaining ground-state pluripotency JP2019500892A (en) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Antibodies that specifically bind to TIM-3 and uses thereof CN115927199A (en) 2015-11-04 2023-04-07 菲特治疗公司 Methods and compositions for inducing hematopoietic cell differentiation CA3003150A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof KR20180096707A (en) 2016-01-20 2018-08-29 페이트 세러퓨틱스, 인코포레이티드 Composition and method for immune cell regulation in adoptive immunotherapy US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors JP7085985B2 (en) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 Preparations and compositions for the treatment of malignant tumors AR108257A1 (en) 2016-05-02 2018-08-01 Mei Pharma Inc POLYMORPHIC FORMS OF 3- [2-BUTIL-1- (2-DIETILAMINO-ETIL) -1H-BENCIMIDAZOL-5-IL] -N-HYDROXY-ACRYLAMIDE AND USES OF THE SAME MX387795B (en) 2016-06-03 2025-03-19 Array Biopharma Inc PHARMACEUTICAL COMBINATIONS. CA3027246A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound JP2019522049A (en) 2016-06-20 2019-08-08 ノバルティス アーゲー Triazolopyridine compounds and uses thereof US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof WO2018065924A1 (en) * 2016-10-04 2018-04-12 Sun Pharmaceutical Industries Limited Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors CN108084078B (en) * 2016-11-24 2021-07-30 中山大学 A kind of synthetic method of drug apremilast for treating psoriatic arthritis disease WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies EP3372624A1 (en) 2017-03-06 2018-09-12 Henkel AG & Co. KGaA One component composition based on compounds with at least two exo-vinylene cyclic carbonate units UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME CN111646946A (en) * 2017-11-14 2020-09-11 深圳市塔吉瑞生物医药有限公司 Substituted benzimidazole compound and composition containing same EP3710053A1 (en) 2017-11-16 2020-09-23 Novartis AG Combination therapies TW201938165A (en) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 Methods and combination therapy to treat cancer MX2020009762A (en) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate. AU2019247498A1 (en) 2018-04-05 2020-11-26 Sumitomo Pharma Oncology, Inc. AXL kinase inhibitors and use of the same KR20210015902A (en) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 PSMA binders and uses thereof AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors MX2021000805A (en) 2018-07-25 2021-05-12 Advanced Accelerator Applications Sa SOLUTIONS OF STABLE AND CONCENTRATED RADIONUCLIDE COMPLEXES. AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same WO2020035779A1 (en) 2018-08-17 2020-02-20 Novartis Ag Urea compounds and compositions as smarca2/brm atpase inhibitors CN117122707A (en) 2018-09-25 2023-11-28 意大利国际先进加速器应用有限公司 combination therapy US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders CN113271945A (en) 2018-12-20 2021-08-17 诺华股份有限公司 Dosing regimens and pharmaceutical combinations comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors CN113490528B (en) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof ES2982474T3 (en) 2019-02-15 2024-10-16 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-1,6-dione derivatives and their uses MX2021009863A (en) 2019-03-21 2021-11-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer. CN113747895A (en) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 Compositions comprising PKM2 modulators and methods of treatment therewith WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds JP2022529985A (en) 2019-04-19 2022-06-27 ヤンセン バイオテツク，インコーポレーテツド How to treat prostate cancer with anti-PSMA / CD3 antibody TWI817018B (en) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 Compounds for the treatment of braf-associated diseases and disorders JP2022539208A (en) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof CN114746414B (en) 2019-09-26 2024-10-18 诺华公司 Aza-quinoline compounds and uses thereof JP2023500906A (en) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Methods of treating cancers with acquired resistance to kinase inhibitors WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof KR20220116522A (en) 2019-12-20 2022-08-23 노파르티스 아게 Use of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use JP2023517393A (en) * 2020-03-17 2023-04-25 メッドシャイン ディスカバリー インコーポレイテッド Proteolytic modifier and method of use thereof US20230165862A1 (en) 2020-04-10 2023-06-01 Taiho Pharmaceutical Co., Ltd. Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor PE20231651A1 (en) 2020-06-09 2023-10-17 Array Biopharma Inc COMPOUNDS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH BRAF JP2023531676A (en) 2020-06-23 2023-07-25 ノバルティス アーゲー Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives AR123185A1 (en) 2020-08-10 2022-11-09 Novartis Ag COMPOUNDS AND COMPOSITIONS TO INHIBIT EZH2 WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers AU2021358394A1 (en) 2020-10-05 2023-04-13 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof CN112759552A (en) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 Synthesis method of semetinib CN112679438A (en) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 Process for the preparation of semetinib US12141240B2 (en) 2021-01-20 2024-11-12 Rutgers, The State University Of New Jersey Method of calibration using master calibration function WO2022159600A1 (en) * 2021-01-21 2022-07-28 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds WO2022162518A2 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof AU2022218128A1 (en) 2021-02-02 2023-08-17 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use JP2024511373A (en) 2021-03-18 2024-03-13 ノバルティス アーゲー Biomarkers and their use for cancer TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations US20240207257A1 (en) * 2021-04-15 2024-06-27 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES MX2023014565A (en) 2021-06-09 2024-02-08 Chugai Pharmaceutical Co Ltd Combination therapy for cancer treatment. WO2022262699A1 (en) * 2021-06-17 2022-12-22 深圳市塔吉瑞生物医药有限公司 Substituted benzimidazole compound, and composition containing same and use thereof WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2 CA3230652A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019 TW202342018A (en) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Inhibitors of mek kinase AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof IL317103A (en) 2022-05-20 2025-01-01 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof WO2024105144A1 (en) 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof